Geode Capital Management LLC bought a new stake in TuHURA Biosciences (NASDAQ:HURA - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 264,915 shares of the company's stock, valued at approximately $1,084,000. Geode Capital Management LLC owned approximately 0.63% of TuHURA Biosciences at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in HURA. Accent Capital Management LLC acquired a new position in shares of TuHURA Biosciences during the 4th quarter worth about $29,000. Charles Schwab Investment Management Inc. purchased a new position in shares of TuHURA Biosciences in the 4th quarter valued at approximately $61,000. Apollon Wealth Management LLC acquired a new position in TuHURA Biosciences in the 4th quarter valued at $253,000. Finally, Suncoast Equity Management purchased a new position in TuHURA Biosciences during the fourth quarter worth about $421,000. 0.62% of the stock is owned by hedge funds and other institutional investors.
TuHURA Biosciences Price Performance
Shares of HURA traded down $0.17 during mid-day trading on Tuesday, reaching $3.73. 62,761 shares of the company's stock were exchanged, compared to its average volume of 256,040. The stock's 50-day simple moving average is $3.40. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $7.93.
Analyst Upgrades and Downgrades
Separately, HC Wainwright cut their price target on shares of TuHURA Biosciences from $13.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, April 3rd.
Get Our Latest Stock Analysis on HURA
TuHURA Biosciences Profile
(
Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Recommended Stories
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
